| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.TRANSPROCEED.2011.02.064 |
| P8608 | Fatcat ID | release_r2vs7sgzi5erjafx4pdp2a274u |
| P698 | PubMed publication ID | 21693335 |
| P2093 | author name string | A Webber | |
| S Chandran | |||
| S J Tomlanovich | |||
| J L Olson | |||
| L Baxter-Lowe | |||
| P2860 | cites work | Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome | Q24685473 |
| The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection | Q28299356 | ||
| De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy | Q33346269 | ||
| Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries | Q33349831 | ||
| Thrombotic microangiopathy after kidney transplantation | Q33372586 | ||
| Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome | Q33375728 | ||
| De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection | Q33390970 | ||
| The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria | Q34567835 | ||
| Intravenous immunoglobulin a natural regulator of immunity and inflammation | Q37544139 | ||
| Therapeutic potential of complement modulation | Q37644190 | ||
| Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access | Q42968367 | ||
| Outcome of Plasma Exchange Therapy in Thrombotic Microangiopathy After Renal Transplantation | Q44596912 | ||
| Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection | Q47869308 | ||
| From humoral rejection to generalized thrombotic microangiopathy--role of acquired ADAMTS13 deficiency in a renal allograft recipient. | Q48275599 | ||
| Complement Mutation-AssociatedDe NovoThrombotic Microangiopathy Following Kidney Transplantation | Q56965937 | ||
| Thrombotic Microangiopathy After Kidney Transplantation | Q57702140 | ||
| Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome | Q84581798 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | kidney transplantation | Q740909 |
| pancreas | Q9618 | ||
| P304 | page(s) | 2097-2101 | |
| P577 | publication date | 2011-06-01 | |
| P1433 | published in | Transplantation Proceedings | Q7834825 |
| P1476 | title | Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation--a case report | |
| P478 | volume | 43 |
| Q48209875 | A case of atypical hemolytic uremic syndrome in a second renal transplant. |
| Q38718092 | Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome-Biomarkers of the Disease and Biopharmaceuticals. |
| Q51333222 | Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab. |
| Q38392458 | Antibody-mediated rejection in pediatric kidney transplantation: pathophysiology, diagnosis, and management |
| Q33411363 | Blood disorders after kidney transplantation |
| Q85570146 | Case report: Eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant |
| Q42086661 | Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea |
| Q26750692 | Critical appraisal of eculizumab for atypical hemolytic uremic syndrome |
| Q27003211 | Current treatment of atypical hemolytic uremic syndrome |
| Q27005877 | De novo glomerular diseases after renal transplantation |
| Q47440056 | De novo thrombotic microangiopathy after kidney transplantation |
| Q33398742 | Drugs that inhibit complement |
| Q52624119 | Early Conversion from Tacrolimus to Belatacept in a Highly Sensitized Renal Allograft Recipient with Calcineurin Inhibitor-Induced de novo Post-Transplant Hemolytic Uremic Syndrome. |
| Q33403196 | Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. |
| Q33425079 | Eculizumab in Transplant-Associated Thrombotic Microangiopathy. |
| Q58608395 | Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use |
| Q89373702 | Haemolytic uraemic syndrome |
| Q33424902 | Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy |
| Q38176005 | Novel immunosuppressive agents in kidney transplantation |
| Q39968188 | Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field |
| Q47104714 | Pharmacologic Complement Inhibition in Clinical Transplantation. |
| Q45736192 | Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody |
| Q37251362 | Prevalence in the General Population of a CFH Sequence Variant Associated with Atypical Haemolytic Uraemic Syndrome in an Extensive Family from Southwest England. |
| Q99361684 | Short Course of Eculizumab May Be Effective in Dialysis-Dependent Transplantation-Associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation: A Case Report |
| Q33406570 | The use of eculizumab in renal transplantation |
| Q58754943 | Thrombotic microangiopathy after renal transplantation: Current insights in and recurrent disease |
| Q42368351 | Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab. |
| Q33403607 | Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies |
Search more.